Edition:
United States

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Global Market

0.48USD
1:11pm EDT
Change (% chg)

$-0.01 (-1.63%)
Prev Close
$0.49
Open
$0.49
Day's High
$0.50
Day's Low
$0.48
Volume
192,190
Avg. Vol
75,247
52-wk High
$13.96
52-wk Low
$0.48

ARGS.OQ

Chart for ARGS.OQ

About

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological... (more)

Overall

Beta: --
Market Cap(Mil.): $20.25
Shares Outstanding(Mil.): 41.36
Dividend: --
Yield (%): --

Financials

  ARGS.OQ Industry Sector
P/E (TTM): -- 29.17 29.94
EPS (TTM): -1.87 -- --
ROI: -118.54 13.48 13.01
ROE: -- 14.39 14.16

BRIEF-Argos Therapeutics board approves plan to streamline operations

* Argos Therapeutics Inc - on March 8, 2017, board approved a workforce action plan designed to streamline operations and reduce company's operating expenses

Mar 09 2017

BRIEF-Argos says independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T

* Independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T in metastatic renal cell carcinoma for futility following its planned interim data review

Feb 22 2017

BRIEF-Argos Therapeutics files for mixed shelf of up to $200 mln

* Files for mixed shelf of up to $200 million - sec filing Source (http://bit.ly/2jbwENR) Further company coverage:

Jan 09 2017

BRIEF-Argos Therapeutics reports Q3 loss per share $0.32

* Argos Therapeutics reports third quarter 2016 financial results and recent operational highlights

Nov 14 2016

More From Around the Web

Earnings vs. Estimates